BLOOD CANCER UK RESEARCH (00738089) is a long-established pri/ltd by guar/nsc (private, limited by guarantee, no share capital) based in LONDON, with over 64 years of operating history since 1962. The company operates in the other research and experimental development on natural sciences and engineering sector. Our database holds 21 signals from 11 official sources covering this company's filings, appointments, and regulatory records. Risk assessment: 85/100 ("robust"), reflecting a strong compliance and financial profile.
Blood Cancer UK Research (00738089) is an active private, limited by guarantee organization without share capital, established in 1962, located in London, focusing on research and experimental development in natural sciences and engineering.
Standard data coverage across 11 sources. Risk score of 85 indicates a strong compliance profile.
BLOOD CANCER UK RESEARCH is 1 of 1,178 other research and experimental development on natural sciences and engineering companies in LONDON, out of 5,671 active companies in this sector nationally (6,605 including dissolved).
The 2 directors of BLOOD CANCER UK RESEARCH are connected to 3 other companies.
None of these connected companies have been dissolved.
BLOOD CANCER UK RESEARCH is listed as the proprietor of 1 property in the HM Land Registry.
Properties are located in West Midlands.
This company profile is built from 9 official data sources: 360Giving, Ch Charges, Ch Officers, Charity Commission, Companies House, GLEIF, Gambling Commission, HM Land Registry, WHOIS.
Blood Cancer UK Research (00738089) is an active private, limited by guarantee organization without share capital, established in 1962, located in London, focusing on research and experimental development in natural sciences and engineering..
Current directors include MR NILS WIEBOLDT, MS JASMINE IONA HANDFORD, MR AMIR SHAH SETHU and 2 more.
BLOOD CANCER UK RESEARCH is registered in LONDON, United Kingdom.
BLOOD CANCER UK RESEARCH operates under SIC code 72190 — Other research and experimental development on natural sciences and engineering.
BLOOD CANCER UK RESEARCH has a risk score of 85 out of 100, classified as "Robust". This score is calculated from 21 data signals across 11 government sources.
The next accounts for BLOOD CANCER UK RESEARCH are due on 31 Dec 2026.
Yes, BLOOD CANCER UK RESEARCH was previously known as BLOODWISE, LEUKAEMIA & LYMPHOMA RESEARCH, LEUKAEMIA RESEARCH FUND LIMITED.
Yes, BLOOD CANCER UK RESEARCH is listed as the proprietor of 1 property in the HM Land Registry, located in West Midlands.
The dissolution rate for the other research and experimental development on natural sciences and engineering sector in the UK is 6.8%. The average company age in this sector is 10.6 years.
BLOOD CANCER UK RESEARCH is currently listed as "Active" on Companies House, indicating it is still a registered company. An "Active" status means the company has not been dissolved, struck off, or entered into liquidation.
BLOOD CANCER UK RESEARCH is registered as a PRI/LTD BY GUAR/NSC (Private, limited by guarantee, no share capital), which is a registered UK business entity.
BLOOD CANCER UK RESEARCH was incorporated on 17 Oct 1962, making it 64 years old. The company remains active and in good standing.
BLOOD CANCER UK RESEARCH is classified under SIC code 72190 (Other research and experimental development on natural sciences and engineering). The Standard Industrial Classification system is used by the UK government to categorise businesses by their primary economic activity.
We track 21 data signals from 11 official government sources for BLOOD CANCER UK RESEARCH.